Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00627640




Registration number
NCT00627640
Ethics application status
Date submitted
13/02/2008
Date registered
3/03/2008
Date last updated
29/03/2013

Titles & IDs
Public title
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
Scientific title
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Secondary ID [1] 0 0
IND: 63,901
Secondary ID [2] 0 0
27919
Universal Trial Number (UTN)
Trial acronym
SETTLE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Idiopathic Parkinson's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Parkinson's disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Safinimide 50-100 mg/day
Treatment: Drugs - Matching Placebo

Experimental: 1 - 1 active (50 - 100 mg/day)

Placebo Comparator: 2 -


Treatment: Drugs: Safinimide 50-100 mg/day
Safinamide, (S)-(+)-2-[4-(3-fluorobenzyloxy) benzylamino] propanamide methanesulfonate, is an a-aminoamide derivative

Treatment: Drugs: Matching Placebo
Matching Placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Evaluate the change from baseline to W24 in daily "on" time ("on" time without dyskinesia plus "on" time with minor dyskinesia)
Timepoint [1] 0 0
24 weeks
Secondary outcome [1] 0 0
Evaluate the changes from baseline to W24 in Activities of Daily Living, cognition, dyskinesias, change in global clinical status, motor symptoms, motor fluctuations, change in levopoda dose and Health Related Quality of life
Timepoint [1] 0 0
24 weeks

Eligibility
Key inclusion criteria
Male and female between the ages of 30 to 80 years with diagnosis of idiopathic Parkinson's
Disease of more than 5 years duration, with a Hoehn and Yahr stage of I-IV during an "off"
phase.

Be levodopa-responsive and have been receiving treatment with a stable dose of levodopa for
at least 4 weeks.

Have motor fluctuations, with >1.5 hours "off" time during the day. Be able to maintain an
accurate and complete diary (18-hour)
Minimum age
30 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Patients with medical conditions and/or taking concomitant medications that would have put
them at risk, interfered with the study evaluations, or made them unable to complete the
requirements of the study;.

Be in a late stage of Parkinson's Disease, and experiencing severe, disabling peak-dose or
biphasic dyskinesia and/or unpredictable or widely swinging fluctuations in their symptoms.

Current diagnosis of substance abuse or history of alcohol or drug abuse in the past 3
months.

Have received treatment with safinamide previously. History of, or current depression
psychosis (e.g. schizophrenia or psychotic depression) Evidence of dementia or cognitive
dysfunction. History of allergic response to anticonvulsants, levodopa, or other
anti-Parkinsonian agents.

Hypersensitivity or contraindications to MAO-B inhibitors. Ophthalmologic history including
any of the following conditions: albino subjects, family history of hereditary retinal
disease, progressive and/or severe diminution of visual acuity (i.e., 20/70), retinitis
pigmentosa, retinal pigmentation due to any cause, any active retinopathy or ocular
inflammation (uveitis), or diabetic retinopathy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2012
Sample size
Target
Accrual to date
Final
549
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [2] 0 0
Central Coast Neuroscience Research - East Gosford
Recruitment postcode(s) [1] 0 0
- Concord
Recruitment postcode(s) [2] 0 0
- East Gosford
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
Tennessee
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
Austria
State/province [17] 0 0
Graz
Country [18] 0 0
Austria
State/province [18] 0 0
Innsbruck
Country [19] 0 0
Belgium
State/province [19] 0 0
Brussels
Country [20] 0 0
Belgium
State/province [20] 0 0
Edegem
Country [21] 0 0
Belgium
State/province [21] 0 0
Hasselt
Country [22] 0 0
Belgium
State/province [22] 0 0
Hoboken
Country [23] 0 0
Belgium
State/province [23] 0 0
Roeselare
Country [24] 0 0
Belgium
State/province [24] 0 0
Wilrijk
Country [25] 0 0
Canada
State/province [25] 0 0
Nova Scotia
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario
Country [27] 0 0
Canada
State/province [27] 0 0
Quebec
Country [28] 0 0
Canada
State/province [28] 0 0
Halifax
Country [29] 0 0
Canada
State/province [29] 0 0
Kingston
Country [30] 0 0
Estonia
State/province [30] 0 0
Tartu
Country [31] 0 0
France
State/province [31] 0 0
Clermont Ferrand
Country [32] 0 0
France
State/province [32] 0 0
Miletrie Poitiers
Country [33] 0 0
France
State/province [33] 0 0
Nantes Cedex
Country [34] 0 0
France
State/province [34] 0 0
Nimes Cedex
Country [35] 0 0
France
State/province [35] 0 0
Pavillon Riser Toulouse
Country [36] 0 0
Germany
State/province [36] 0 0
Beelitz-Heilstaetten
Country [37] 0 0
Germany
State/province [37] 0 0
Berlin
Country [38] 0 0
Germany
State/province [38] 0 0
Goettingen
Country [39] 0 0
Germany
State/province [39] 0 0
Leipzig
Country [40] 0 0
Germany
State/province [40] 0 0
Marburg
Country [41] 0 0
Germany
State/province [41] 0 0
Mittweida
Country [42] 0 0
Germany
State/province [42] 0 0
Muenchen
Country [43] 0 0
Germany
State/province [43] 0 0
Tubingen
Country [44] 0 0
Germany
State/province [44] 0 0
Ulm
Country [45] 0 0
Germany
State/province [45] 0 0
Wiesbaden
Country [46] 0 0
Hungary
State/province [46] 0 0
Budapest
Country [47] 0 0
Hungary
State/province [47] 0 0
Debrecen
Country [48] 0 0
Hungary
State/province [48] 0 0
Miskolc
Country [49] 0 0
Hungary
State/province [49] 0 0
Móricz
Country [50] 0 0
Hungary
State/province [50] 0 0
Peterfy Sandor
Country [51] 0 0
Hungary
State/province [51] 0 0
Sopron
Country [52] 0 0
Hungary
State/province [52] 0 0
Szentpetri
Country [53] 0 0
India
State/province [53] 0 0
Andh Prad
Country [54] 0 0
India
State/province [54] 0 0
Delhi
Country [55] 0 0
India
State/province [55] 0 0
Karna
Country [56] 0 0
India
State/province [56] 0 0
Mangalore
Country [57] 0 0
India
State/province [57] 0 0
Mumbai Mahara
Country [58] 0 0
India
State/province [58] 0 0
Nagpur
Country [59] 0 0
India
State/province [59] 0 0
Vellore
Country [60] 0 0
Israel
State/province [60] 0 0
Ashkelon
Country [61] 0 0
Israel
State/province [61] 0 0
Haifa
Country [62] 0 0
Israel
State/province [62] 0 0
Petach-Tikva
Country [63] 0 0
Israel
State/province [63] 0 0
Ramat-Gan
Country [64] 0 0
Israel
State/province [64] 0 0
Tel Aviv
Country [65] 0 0
Israel
State/province [65] 0 0
Zefat
Country [66] 0 0
Korea, Republic of
State/province [66] 0 0
Seoul
Country [67] 0 0
Malaysia
State/province [67] 0 0
Kuala Lumpur
Country [68] 0 0
Malaysia
State/province [68] 0 0
Pinang
Country [69] 0 0
Netherlands
State/province [69] 0 0
Hertogenbosch
Country [70] 0 0
New Zealand
State/province [70] 0 0
Aucklan
Country [71] 0 0
New Zealand
State/province [71] 0 0
Christchurch
Country [72] 0 0
New Zealand
State/province [72] 0 0
Hamilton
Country [73] 0 0
Slovakia
State/province [73] 0 0
Banska Bystrica
Country [74] 0 0
Slovakia
State/province [74] 0 0
Bratislava
Country [75] 0 0
Slovakia
State/province [75] 0 0
Levoca
Country [76] 0 0
Slovakia
State/province [76] 0 0
Slovak Republic
Country [77] 0 0
Spain
State/province [77] 0 0
Madrid
Country [78] 0 0
Spain
State/province [78] 0 0
Malaga
Country [79] 0 0
Spain
State/province [79] 0 0
San Sebastian
Country [80] 0 0
Switzerland
State/province [80] 0 0
Bern
Country [81] 0 0
Switzerland
State/province [81] 0 0
Geneve
Country [82] 0 0
Taiwan
State/province [82] 0 0
Chang Hua
Country [83] 0 0
Taiwan
State/province [83] 0 0
Kaohsiung
Country [84] 0 0
Taiwan
State/province [84] 0 0
Taipei
Country [85] 0 0
Thailand
State/province [85] 0 0
Bangkok
Country [86] 0 0
Thailand
State/province [86] 0 0
Lampang
Country [87] 0 0
Thailand
State/province [87] 0 0
Ubonratchathani
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Blackpool
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Cambridge
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Glasgow
Country [91] 0 0
United Kingdom
State/province [91] 0 0
London
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Newcastle Upon Tyne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Newron Pharmaceuticals SPA
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Parkinson's Disease is a major neurodegenerative disorder in which there is a progressive
loss of dopamine-containing neurons. The understanding that PD is a syndrome of dopamine (DA)
deficiency led to the introduction in the clinical practice of L-dopa, a precursor of DA that
crosses the blood brain barrier, and also to the use of selective inhibitors of MAO-B, the
major DA metabolising enzyme in man.

Safinamide is an inhibitor of MAO-B. This is a phase III trial to evaluate the efficacy and
safety of safinamide (50 and 100 mg p.o. q.a.m.) compared to placebo as add-on therapy to a
stable dose to levodopa in subjects with advance idiopathic Parkinson's Disease.

The principal efficacy measure is the increase in mean daily "on" time during the 18-hr diary
recording period.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00627640
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Algirdas Kakarieka, MD
Address 0 0
Merck Serono S.A., Geneva
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00627640